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Introduction and Background 
In 2001 it was estimated that 46.2 million adults in the United States smoke 
cigarettes (Centers for Disease Control and Prevention Cigarette Smoking Among 
Adults—United States, 2001, 2003). Of these adults 70% want to quit smoking and 46% 
try to quit smoking each year with only 2.5% able to quit permanently (Fiore, 2000; 
Sweeney, Fant, Fagerstrom, McGovern, & Henningfield, 2001).  
Smoking cigarettes poses an extraordinary hazard not only to those that smoke 
cigarettes but also to persons who are exposed to second hand smoke.  Smoking 
cigarettes is known to cause chronic lung disease, heart disease, stroke, and cancer of 
the lung, larynx, esophagus, mouth, and bladder. It also contributes to the development 
of cancer of the cervix, pancreas and kidney. In addition, second hand smoke poses a 
significant health risk with an estimated 3,000 non-smokers dying of lung cancer each 
year and greater than 35,000 dying of heart disease. Up to 300,000 children experience 
respiratory tract infections due to exposure to second hand smoke. Babies born to 
women who smoked during pregnancy are at higher risk for low birth weight, SIDS, and 
respiratory distress. Smoking related illnesses cost the nation greater than $150 billion 
each year and currently cigarette smoking is responsible for 1 in 5 deaths (Centers for 
Disease Control and Prevention Targeting Tobacco Use: The Nation’s Leading Cause 
of Death, 2003).  
The main substance responsible for tobacco dependence is nicotine. As such, 
nicotine replacement therapy (NRT) has been developed and has proved to be a means 
to control withdrawal symptoms related to tobacco dependence and to aid persons in 
smoking cessation (Houezec, 2003). Patients using NRT improve the likelihood of 2 
remaining abstinent at one year, at a rate 1.5 to 2.7 times higher than those using 
placebo (Sims & Fiore, 2002). Common symptoms of nicotine/tobacco withdrawal 
include craving, weight gain, insomnia, irritability, depressed mood, frustration, anger, 
anxiety, difficulty in concentrating, and restlessness. These symptoms can be 
unrelenting and make it quite difficult for cigarette smokers to abstain from repeated 
tobacco use even after the utilization of pharmacotherapy (Sweeney et al., 2001). 
These same withdrawal symptoms also in part explain a very high relapse rate, with 
some studies reporting relapse rates up to 80% in the first year following cessation 
(Sims & Fiore, 2002). Currently, there are six first line therapies indicated to aid patients 
in smoking cessation, five that are nicotine containing and one that is not. The five 
nicotine containing FDA approved methods of nicotine replacement therapy are nicotine 
gum, inhaler, patch, nasal spray and lozenge. The non-nicotine containing therapy is 
bupropion SR (Zyban) (Centers for Disease Control and Prevention Coverage For 
Tobacco Use Cessation Treatments, 2004). Bupropion SR is hypothesized to be 
effective for smoking cessation by enhancing dopaminergic activity, as it is a selective 
reuptake inhibitor of both dopamine and norepinephrine (Sutherland, 2002).   
The physiological basis for nicotine replacement is two-fold. Consumers who 
regularly use tobacco products maintain high daily levels of nicotine and experience 
transient bursts of elevated nicotine levels throughout the day (Sweeney et al., 2001). 
None of the aforementioned therapies, when used singly, has the capability to duplicate 
the dual effects of nicotine tobacco users achieve with chronic use of tobacco products. 
Recent studies have shown that combination NRT is more effective for smoking 
cessation than monotherapy (“New Tools to help you quit smoking,” 1999).  3 
It is the responsibility of all health care professionals to offer repeated guidance, 
support, and advice in regard to the importance of smoking cessation and offer the best 
possible means by which patients may succeed in abstaining from smoking cigarettes. 
Health care professionals may not be utilizing the most effective methods available to 
help chronic tobacco users quit, for a number of reasons. ‘Nicotine dependence’ and 
‘Nicotine withdrawal’ are now designated as medical conditions by the DSM-IV of the 
American Psychological Association (Sweeney et al., 2001). Nicotine dependence is 
just that, a dependence, and should be viewed in the same light as patients who suffer 
from opiate, amphetamine or cocaine dependence. It is a chronic condition in which 
remissions and relapses are to be expected. It is thought that clinicians do not think of 
tobacco dependence in this light and are therefore discouraged when patients relapse 
to tobacco use and perhaps do not revisit quitting with them again (Fiore, 2000). It is 
also thought that clinicians do not discuss NRT with patients who want to try to quit 
smoking, for a few reasons. First, NRT is available over-the-counter (OTC) and 
classically clinicians are more inclined and/or informed to discuss prescription options 
first. Second, they may lack knowledge of how to tailor OTC NRT to a patient’s 
individual needs, including combination therapy. And lastly, they may be hesitant to 
prescribe NRT to patients with known heart disease.   
The role that nicotine plays in smoking related illness is misunderstood. Nicotine 
is responsible for the addictive properties of tobacco use, however it is the tar, carbon 
monoxide, and other harmful gases taken in with the nicotine that cause chronic 
bronchitis, emphysema and lung cancer. Nicotine has been shown to exert 
cardiovascular effects and has been recognized as an agent that may precipitate a 4 
cardiovascular event. The mechanism of action being, production of a hypercoagulable 
state, that may promote thrombosis. However, this phenomenon is associated with a 
bolus dose of nicotine achieved through cigarette smoke and is not associated with 
gradual delivery of nicotine via NRT (Houezec, 2003). Although recent studies have 
shown that combination NRT can increase abstinence rates up to 15% over 
monotherapeutic NRT, it currently is not FDA approved. Labels on various products do 
not promote combination NRT use and in fact warn consumers against it (Sweeney et 
al., 2001). Despite this current lack of FDA approval, combination therapy should be 
considered for all patients on an individualized basis, especially those who have a 
significant history of tobacco use and for those who have failed monotherapy.     
The effects of smoking cigarettes and second hand cigarette smoke are harmful 
to all that are exposed to it. It is estimated that 442,398 deaths are attributable to 
cigarette smoking each year (Centers for Disease Control and Prevention Targeting 
Tobacco Use: The Nation’s Leading Cause of Death, 2003). It is the responsibility of 
physician assistants and all health care personnel to encourage and support smokers in 
their efforts to quit, employing the most effective strategies available. ‘Tobacco 
dependence is a complex mixture of pharmacological, psychological and social 
components (Houezec, 2003). The scope of this article will focus on the 
pharmacological aspects of nicotine dependence and will review currently available 
therapies for smoking cessation and how these aids may best be employed to improve 
smoking cessation rates.  5 
Pharmacokinetics of Nicotine 
Tobacco products are widely recognized as highly addictive agents.  As noted 
previously, nicotine has been implicated as the primary addictive ingredient in tobacco 
products. It is important to note that the abuse potential of an agent is related to the time 
between administration and the resulting positive reinforcing effects. In this light, 
smoking in particular proves to be exceptionally addictive as it is rapidly absorbed via 
the pulmonary venous system and reaches the brain in 10-20 seconds. This is more 
rapid than the intravenous administration and systemic venous absorption of nicotine.   
Nicotine is a weak base that rapidly crosses membranes at physiologic blood pH 
(7.4). It also readily crosses the basic oral and nasal mucous membranes. Absorption is 
further facilitated by the thin epithelium and rich blood supply of these mucous 
membranes. Because smoking behavior varies greatly from person to person, it is hard 
to predict nicotine exposure on an individual basis. However, it is estimated that on 
average, smokers absorb about 1mg of nicotine per cigarette. The liver is the primary 
site of nicotine metabolism and its elimination half-life is two hours. With an elimination 
half-life of two hours and regular smoking it is consistent that blood nicotine levels 
increase over 6-8 hours.  Average afternoon blood nicotine levels range from  
10-50 ng/mL. In addition, depending on how cigarettes are smoked, they allow 
incremental peaks in blood nicotine concentrations of 5-30 ng/mL. Blood nicotine 
concentrations then fall throughout the night leaving smokers with little nicotine in their 
systems come morning (Houezec, 2003).   6 
Nicotine Replacement Therapy 
For more than twenty years, nicotine replacement therapy has been used to treat 
tobacco dependence (Haustein, Krause, Haustein, Rasmussen, & Cort, 2003).  It 
remains the mainstay of treatment with proven pharmacological efficacy in randomized 
clinical trials doubling cessation rates in active versus placebo groups (Hurt, 1999). As 
noted earlier, there are five nicotine containing FDA approved methods of nicotine 
replacement therapy available on the market.  Studies have shown that all forms of NRT 
are equally effective as part of a strategy for smoking cessation (Diefenbach, Smith, & 
Nahelsky, 2003). A randomized comparative trial of nicotine gum, nicotine nasal spray, 
nicotine transdermal patch, and nicotine inhaler concluded that perceived helpfulness, 
effects on craving, withdrawal symptoms and abstinence rates were similar among the 
four therapies (Hajek, West, Foulds, Nilsson, Burrows, & Meadow, 1999). In another 
study, West, Hajek, Nilsson, Foulds, May, & Meadows (2001) were interested in 
individual preferences and responses to nicotine gum, patch, nasal spray and inhaler 
and found that successful cessation was not related to a patient obtaining their first 
choice nicotine replacement product. Despite these findings, it is important to note that 
the rate of nicotine delivery, based on the pharmacokinetic properties of the different 
delivery systems available, proves to be a major difference between NRT products (Hurt 
et al., 1998). Patient needs, tolerability and cost should be considered when deciding 
which form of therapy is appropriate.  These matters as well as method and onset of 
action, dosing, adverse reactions and cautions will be discussed for all the therapies 
reviewed in this article.  
 7 
Nicotine Gum 
  Available since 1984, nicotine polacrilex gum is the oldest of the nicotine 
replacement product preparations (Hurt, 1999; Watts, Noble, Smith, & Disco, 2002). It 
became available over the counter in 1996 in two doses: 2-mg and 4-mg (Thompson & 
Hunter, 1998). The 2-mg dose is recommended for smokers smoking 1-24 cigarettes 
per day. The 4-mg dose is recommended for heavier smokers (>24 cigarettes per day) 
(Watts et al., 2002). Recommended duration of treatment is twelve weeks. The dosing 
schedule is as follows: chew one piece every 1-2 hours for the first six weeks of 
treatment, then one piece every 2-4 hours for the next three weeks, and finally one 
piece every 4-8 hours for the final three weeks. Maximum daily dosage should not 
exceed 24 pieces of gum (Sims & Fiore, 2002).   
Pharmacologically, nicotine is absorbed slowly through the buccal mucosa with 
peak nicotine concentrations achieved 30 minutes after starting chewing.  The gum 
provides replacement of approximately 30-64% of pre-cessation nicotine plasma 
concentrations. Adverse events associated with nicotine gum use include sore mouth or 
sore throat, dyspepsia, nausea, hiccups, flatulence, diarrhea and oral blisters. Under-
dosing is a problem associated with nicotine gum use. Patients must also take special 
care to avoid acidic beverages while using the gum as they can impair the absorption of 
nicotine. Advantages of nicotine gum use include delayed weight gain, high patient 
tolerability, and patient control of nicotine intake. Approximate cost per day is $5.23 for 
10, 2-mg pieces and $5.90 per day for 10, 4-mg pieces (Thompson & Hunter, 1998; 
Watts et al., 2002).      8 
Nicotine Patch 
  The nicotine transdermal patch became available in the US as an aid to smoking 
cessation in 1991. It has been available over-the-counter since 1999 (Watts et al., 
2002). There are four FDA approved patches available (Thompson & Hunter, 1998). 
The two patches available over-the-counter come in the following strengths: 5, 7, 10, 
14, 15, and 21 mg.  The recommended dosing schedule is 21mg/day for 6 weeks, then 
14 mg/day for 2 weeks, followed by 7 mg/day for 2 weeks, then discontinue. A lower 
dose regimen for those smoking <10 cigarettes per day is 14mg/day for 6 weeks, then 7 
mg/day for 2 weeks.  The patches are worn for 16 hours or 24 hours a day, as directed 
for 8-10 weeks (Murphy, 2004).   
The patches work by delivering a fixed dose of nicotine transdermally at a 
constant rate. Following patch application, plasma nicotine concentrations begin to rise, 
slowly peaking in 4-8 hours. It takes 2-3 days after initiation of therapy to reach steady 
state nicotine concentrations (Thompson & Hunter, 1998). In those who smoke a pack 
of cigarettes per day, standard dose patch therapy provides a median percent nicotine 
replacement of about 50% (Hurt, 1999). Advantages of the nicotine patch include ease 
of use and greater patient compliance attributed to once-a-day dosing. Local adverse 
effects associated with use of the patch include skin irritation at the application site to 
include erythema, burning, pruritis, edema, and less often vesicles. Insomnia, abnormal 
dreams, headache, nausea, and vertigo are associated systemic effects (Dale, Ebbert, 
Hays, & Hurt, 2000; Thompson & Hunter, 1998). An important disadvantage associated 
with use of the nicotine patch is that of its inability to respond to patient’s urges to 9 
smoke due to its steady method of nicotine delivery (Houezec, 2003). Approximate cost 
per day is $3.50-$3.89 (Watts et al., 2002). 
 
Nicotine Nasal Spray 
  Nicotine nasal spray was approved as a treatment for nicotine dependence in the 
United States in 1996 and became available by prescription in 1997 (Thompson & 
Hunter, 1998; Watts et al., 2002). Today its accessibility remains by prescription only. 
The nasal spray is the only smoking cessation medication available whose 
pharmacological profile most closely mimics that of smoking a cigarette. It is available in 
a 10ml spray bottle that contains a water-based buffered solution, which contains 
100mg of nicotine (Sims & Fiore, 2002; Thompson & Hunter, 1998). One spray is 
designed to deliver 0.5mg of nicotine; one dose is considered one spray in each nostril, 
which therefore delivers 1mg of nicotine. Recommended treatment is 1-2 doses per 
hour with a maximum of 5 doses/hr and 40 doses/day for 3 months (Murphy, 2004).    
Nicotine is rapidly absorbed via the nasal mucosa with peak concentrations 
reached in 5-10 minutes. This rapid absorption is especially useful for treatment of the 
highly dependent smoker. Advantages of the nasal spray include on demand self-
administration of nicotine to satisfy patient’s urges to smoke and venous plasma 
concentrations of nicotine similar to that of 2mg nicotine gum (Thompson & Hunter; 
Houezec, 2003). A single 1mg dose of the nasal spray produces peak venous nicotine 
concentrations of 2-12 ng/ml and has been reported to provide more immediate relief of 
craving for a cigarette versus a single dose of 4mg nicotine gum (Hurt et al., 1998). 
Although adverse affects associated with use of the nasal spray usually subside in the 10 
first week of use, most users report nasal and throat irritation, runny nose, sneezing, 
watery eyes, and cough. Patients with nasal or sinus problems, allergies, or asthma 
should consider alternative treatments as the nasal spray could exacerbate these 
conditions. Underadministration remains a problem associated with the nasal spray. 
Average cost per day, with an estimated 8 to 40 doses administered per day is $3.27 to 
$16.33 (Watts et al., 2002).  
 
Nicotine Inhaler 
  In 1998, the nicotine inhaler became available by prescription in the United 
States to treat tobacco dependence (Watts et al., 2002). It remains a prescription only 
medication today. The inhaler, which resembles a cigarette, consists of a plastic 
mouthpiece and a cartridge. The cartridge contains 10mg of nicotine and 1mg of 
menthol. Though the cartridge contains 10mg of nicotine, it delivers only 4mg. The 
nicotine inhaler differs from cigarette smoking and traditional inhalers in that the device 
is meant to deliver vaporized nicotine to the buccal mucosa, not inhaled into the lungs 
(Okuyemi, Ahluwalia, & Wadland, 2001; Dale et al., 2000). Absorption is slow with rates 
similar to that of nicotine gum (Dale et al., 2000). The recommended dosage is 6 to 16 
cartridges per day for 12 weeks duration. If needed, treatment can then be tapered over 
another 12-week period with a maximum of 6 months of therapy (Murphy, 2004). 
Compared with customary cigarette smoking, the ad lib use of the inhaler provides 
about 33% nicotine replacement (Rennard & Daughton, 2003).   
An advantage of the nicotine inhaler is that its use mimics some of the behavior 
routines associated with cigarette smoking (Dale et al., 2000). As with other NRT’s, 11 
underuse of the inhaler remains a problem. Reported adverse events include mouth and 
throat irritation, and cough (Watts et al., 1998). Use of the inhaler should be avoided in 
persons with reactive airway disease as any inhaled nicotine can cause bronchospasm 
(Rennard & Daughton, 2003). Cost per day with average use of the nicotine cartridges 
(6-16 cartridges/day) ranges from $5.82 to $15.52 (Watts et al., 1998). 
 
Nicotine Lozenge 
  In 2002, nicotine polacrilex lozenges received FDA approval for over-the-counter 
marketing of the product for smoking cessation. It is available in 2mg and 4mg doses 
and has demonstrated efficacy similar to that of nicotine gum (Rennard & Daughton, 
2003; Murphy, 2004). Dosing is determined by the patient’s smoking history. For 
persons who smoke within 30 minutes of waking, the recommended dose is 4mg and 
likewise for persons smoking beyond 30 minutes from waking, the recommended dose 
is 2mg. The dosing schedule is to dissolve one lozenge in the mouth every 1-2 hours, 
with a minimum of 9 lozenges used daily, for 6 weeks, then one lozenge every 2-4 
hours for 3 weeks and finally one lozenge every 4-8 hours for 3 weeks. Duration of 
therapy is recommended for 12 weeks. An advantage of lozenge use includes patient 
control of amount and time of dosing, which can be accomplished on demand. In 
addition, when compared with equal dosing of nicotine gum the lozenge has to offer 
about 25% more nicotine replacement (Shiffman, Dresler, Hajek, Gilburt, Targett, & 
Strahs, 2002). Patients are to avoid eating and drinking 15 minutes prior to and during 
use of the lozenge and are to minimize swallowing. Adverse reactions include mouth 12 
and throat irritation, headache, hiccups, dizziness, upset stomach, hypertension and 
dizziness (Murphy, 2004).  13 
Non-nicotine Replacement Therapy 
Bupropion Hydrochloride 
 Bupropion  hydrochloride  has been used in the United States for about 15 years 
as a treatment for major depression (Rennard & Daughton, 2004). Though there is a 
strong correlation between tobacco users and past history of depression, bupropion 
appears to be equally effective in patients, regardless of past history of depression. This 
implies that its ability to aid in smoking cessation is not related to its antidepressant 
effects (Hurt, 1999; Sutherland, 2002). Classified as an atypical antidepressant, its 
exact mechanism of action in regards to aiding smoking cessation is unclear, but it has 
been proven effective in double-blind placebo controlled trials (Martinez-Raga, Keaney, 
Sutherland, Perez-Galvez, & Strang, 2003). It has been hypothesized that bupropion 
works to ameliorate nicotine withdrawal symptoms by inhibiting the reuptake of the 
neurotransmitters norepinephrine, dopamine, and to a lesser degree serotonin.   
However, a recent study suggests that instead of inhibiting reuptake, bupropion may 
directly stimulate the release of norepinephrine, which in turn mounts an excitatory 
effect on serotonin releasing neurons, not dopamine releasing neurons. This suggests 
that the major action of bupropion is on the serotonergic system (Martinez-Raga et al., 
2003). Bupropion is the first and only non-nicotine containing FDA approved medication 
used to treat nicotine dependence (Martinez-Raga et al., 2003; Dale et al., 2000). It 
gained FDA approval in 1997 and is available by prescription only in a 150mg sustained 
release formulation (bupropion SR) (Gold, Rubey, & Harvey, 2002; Murphy, 2004). 
Initial dosing for patients that are at least 18 years of age is 150mg daily for 3 days, then 
150mg twice daily thereafter. Maximum daily dose should not exceed 300mg and each 14 
dose should be separated by at least 8 hours time. Patients are to set a quit day within 
1-2 weeks of initiating therapy. Therapy is recommended for 7-12 weeks duration, 
although the exact, most efficacious duration of treatment is unknown (Murphy, 2004; 
Rennard & Daughton, 2003). Current recommendations state that continuation of 
treatment for an additional 6 months or indefinitely is a reasonable option for patients 
that were able to quit successfully after the standard treatment regimen (Sims & Fiore, 
2002; Barringer & Weaver, 2002).  Conversely, if patients are still smoking after 7 
weeks of treatment with bupropion, the medication should be discontinued at that time.   
Following administration of a single 150mg dose of bupropion SR, peak plasma 
concentrations of the drug are achieved in about 3 hours (Martinez-Raga et al., 2003). 
Bupropion is an effective treatment option for patients who desire non-nicotine 
containing therapy or could not tolerate or failed NRT (Okuyemi et al., 2001; Sutherland, 
2002). Adverse effects associated with use of bupropion are mild and may include 
insomnia, dry mouth, anxiety, headache and rash (Sutherland, 2002). There is a seizure 
risk associated with use of bupropion. Although the estimated risk of seizure is similar to 
that of other antidepressant medications bupropion is contraindicated in patients with a 
history of seizure disorder (Peters & Morgan, 2002). Scenarios in which a patient’s 
seizure threshold may be lowered are also contraindications to the use of bupropion.  
This may include use of medications such as monoamine oxidase (MAO) inhibitors, or 
the existence of the following conditions: eating disorder, alcohol abuse, CNS tumor, 
history of head trauma, type 1 or 2 diabetes, cirrhosis, or bipolar disorder (Martinez-
Raga et al., 2003). The approximate cost of bupropion SR is $1.60/150mg.  Therefore, 
the first 3 days of therapy with once daily dosing of 150mg will cost $1.60/day. 15 
Treatment thereafter, with twice daily dosing (300mg) will cost $3.20/day (Watts et al., 
2002). 16 
Combination Therapy 
A number of studies have been published within the past 10 years evaluating the 
effects of combination therapy on smoking cessation. Suppression of nicotine 
withdrawal symptoms as well as smoking cessation rates are usual primary outcomes of 
interest of the studies. Employing the use of 2 NRTs simultaneously has been reported 
to increase cessation rates an additional 5-10% (Gold et al., 2002). Though current 
product information does not endorse the simultaneous use of different NRT 
formulations, there is a pharmacological basis for employing combination NRT (Peters 
& Morgan, 2002). Especially combining therapies that couple a long acting formulation 
(nicotine patch), with a shorter acting formulation (nicotine gum, nicotine nasal spray, or 
nicotine inhaler), the latter being used on an as-needed basis (Hurt, 1999). Efficacy is 
improved using combinations such as these (Okuyemi et al., 2001). Another rationale 
for employing combination NRT is that dual therapy provides enhanced withdrawal 
control, as current NRT formulations used alone provide less than half of the nicotine 
plasma concentrations moderate to heavy smokers are familiar with from cigarettes 
(Cinciripini, 1999; Stapleton, 1999). Further studies have investigated the merit of 
combining NRT (nicotine patch) with bupropion. There is rationale to combine these 
medications, as each act on different parts of the brain (Hurt, 1999). Current 
recommendations suggest reserving combination therapy for moderate or highly 
dependent smokers who were unable to quit with a single agent and suffered significant 
withdrawal (Okuyemi et al., 2001; Peters & Morgan, 2002). Special attention must be 
made when considering combination therapy as the use of two agents simultaneously 
could be cost prohibitive (Watts et al., 2002).   17 
Nicotine patch + Nicotine gum 
  Nicotine patch in combination with nicotine gum has been shown to increase 
smoking abstinence rates as well as reduce nicotine withdrawal symptoms compared 
with either treatment alone (Sweeney et al., 2001). The average nicotine substitution for 
the combined therapy has been found to be 61.7% versus 39.8% replacement for patch 
only therapy. Abstinence rates for the combination therapy have been demonstrated to 
be up to 50% greater than patch only therapy and are statistically significant up to 24 
weeks (Kornitzer, Boutsen, Dramaix, Thijs, & Gustavsson, 1995). 
Nicotine patch + Nicotine nasal spray 
  Blondal, Gudmundsson, Olafsdottir, Gustavsson, and Westin (1999) found that 
using combination nicotine patch for 5 months with continued use of nicotine nasal 
spray for one year resulted in greater efficacy for smoking cessation versus using patch 
only therapy. Abstinence rates for the combination therapy were doubled and tripled 
during the active treatment phase of the study. Furthermore, long-term follow up 
abstinence rates of study subjects who received the combination therapy were doubled. 
Subjects receiving combination therapy were afforded nicotine replacement greater than 
50% of smoking concentrations (Stapleton, 1999). Another study by Croghan et al. 
(2003), found that combining the nicotine patch with the nicotine nasal spray was more 
efficacious for achieving smoking abstinence compared to either therapy alone, though 
the results were only significant for a short time.  
 
 
 18 
Nicotine patch + Nicotine inhaler 
  In accordance with the dual therapies described above, nicotine patch in 
combination with nicotine inhaler has also been reported to be a more effective method 
for improving smoking abstinence rates versus use of the nicotine inhaler only.  As 
described by Bohadana, Nilsson, Rasmussen, & Martinet (2000), short (6 weeks) and 
long (12 months) term abstinence rates were consistently higher in subjects who 
received both forms of NRT. The combination was also reported to provide greater than 
50% nicotine replacement of prior smoking levels (Bohadana et al., 2000).   
 
Nicotine patch + Bupropion 
  Bupropion SR in combination with the nicotine patch has demonstrated 
abstinence rates superior to that of therapy with nicotine patch alone or placebo in a 
randomized clinical trial. However, these findings were not significant when compared 
with abstinence rates achieved with the use of Bupropion SR alone. (Jorenby et al., 
1999). In a similar more recent naturalistic study, Gold et al. (2002) found comparable 
abstinence rates across treatment groups with again the combination therapy achieving 
the highest abstinence values.     
 
 
 
 
 19 
Methodology 
A review was undertaken of the relevant smoking cessation literature from  
1995-present. Journal articles were searched using PubMed, Medline, CINAHL, and 
UpToDate databases using key words such as: Nicotine, Nicotine Replacement, 
Smoking Cessation, Combination Therapy, & Combined Modality Therapy. Selection of 
articles was limited to those printed in the English language.   20 
Discussion 
  Based on the current literature, there is evidence to support NRT products as 
equally effective therapies for the treatment of tobacco dependence that improve 
abstinence rates as well as alleviate nicotine withdrawal symptoms. Bupropion SR, a 
nicotine free therapy, has also proved to be an efficacious medication for the treatment 
of tobacco dependence. It alleviates withdrawal symptoms and as with NRT 
approximately doubles abstinence rates (Fiore, 2000). The efficacy of combining 
therapies has also been established and has demonstrated cessation rates that are 
double those of single therapy regimens. These results demonstrate efficacy 
comparable to monotherapy versus placebo (Stapleton, 1999). 
  Weight gain is a common association and concern with regards to smoking 
cessation. Average weight gain upon stopping smoking is between 8-11 pounds.  All of 
the NRTs have been shown to delay but do not prevent weight gain (Diefenbach & 
Smith, 2003; Rennard & Daughton, 2004). In addition, a randomized, placebo-controlled 
trial found that patients treated with bupropion for one year experienced less weight 
gain over time versus those who received placebo (Rennard & Daughton, 2004). 
Furthermore, Jorenby et al. (1999) reported patients treated with the combination of 
nicotine patch and bupropion experienced the least amount of weight gain compared 
with treatment groups that received either monotherapy or placebo. These results were 
statistically significant for 7 weeks of therapy. Regardless of weight gain, the 
advantages of quitting smoking are far greater than the disadvantages associated with a 
modest amount of weight gain (Rennard & Daughton, 2004).         
 21 
Conclusion 
Smoking cigarettes and the use of tobacco products in general are known 
causative agents for significant unfavorable health and welfare conditions, not only for 
users but also for those who are environmentally exposed to tobacco. Nicotine 
dependence is the most common psychiatric disorder and is recognized as a chronic 
addiction (Martinez-Raga, 2003). As brief intervention from a health care professional 
has been reported to increase smoking cessation rates, it is our responsibility to 
routinely screen for tobacco use and determine smoking status of all patients. It is even 
recommended that smoking status be incorporated into the vital signs so to assure this 
assessment is conducted routinely (Sutherland, 2002). This is critical information 
because smokers do not generally seriously attempt quitting smoking more than once 
per year (Jamerson et al., 2001). Complete abstention from tobacco products must be 
encouraged as the harm reduction of smoking fewer cigarettes is unknown (Peters & 
Morgan, 2002). It has been reported that 97% of quit attempts are unsuccessful without 
the aid of therapy (Shiffman et al., 2002). With the exception of certain patient 
populations who may require special consideration before employing pharmacotherapy, 
any of the FDA approved therapies for smoking cessation should be utilized to aid 
patients who are motivated to quit. Exceptional patient populations include, those with 
medical contraindications to pharmacotherapy, pregnant or breast feeding women, 
adolescents and patients smoking less than 10 cigarettes per day (Fiore, 2000).   
It is important to remember and acknowledge that nicotine has mood modulating 
effects. Smokers would not continue smoking if nicotine did not have this capability. 
Tobacco users rapidly experience feelings such as a heightened sense of alertness and 22 
pleasure, which is powerfully reinforcing (Cinciripini, 1999; “New Tools to help you quit 
smoking,” 1999). Following smoking cessation, the maximum intensity of withdrawal 
symptoms peaks in 24-48 hours and gradually declines over 2 weeks (Thompson & 
Hunter, 1998). Combination therapy may be especially useful in these first couple 
critical weeks following smoking cessation because of its increased capability to 
suppress nicotine craving and withdrawal symptoms by providing higher concentrations 
of nicotine replacement (Haustein et al., 2003; Stapleton, 1999). Patients and clinicians 
must equally understand that pharmacotherapy will help alleviate withdrawal symptoms, 
not eliminate them (Campbell, 2000). Following cessation, ex-smokers can expect the 
desire to smoke to persist for months to years (Thompson & Hunter, 1998). 
Experimentation with smoking should be strongly discouraged, as it more often 
than not results in relapse (Cinciripini, 1999). Unfortunately, these factors most likely 
account for the unfavorable statistic that, regardless of intervention and initial success, 
80% of smokers will relapse within a 12-month period (Jamerson et al., 2001). Despite 
this figure, understanding that nicotine addiction is a true dependence, visiting smoking 
status routinely, utilizing the most effective smoking cessation strategies currently 
available, and ensuring prompt, repeated follow-up care are all things clinicians can do 
to continually promote and increase smoking cessation rates.        23 
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Abstract 
Objective. Review current smoking cessation literature to determine the most effective 
strategies available to increase smoking cessation rates. Method. Relevant articles from 
the past 10 years were obtained and reviewed. Results. All six FDA approved first line 
therapies available to aid patients in smoking cessation are efficacious and improve 
cessation rates. Combination therapy has demonstrated greater efficacy for smoking 
cessation over monotherapy. Conclusion. Smoking cigarettes poses an extraordinary 
hazard not only to those that smoke but also to persons who are exposed to 
environmental tobacco smoke. Smokers must be routinely identified and encouraged to 
quit. Nicotine replacement therapy and bupropion are effective therapies to benefit 
smoking abstinence. Utilizing combination therapy as first line treatment for smokers 
who are motivated to quit, especially in the first few critical weeks following smoking 
cessation, may provide greater relief of withdrawal symptoms and improve long term 
cessation success.  